L-arginine hexanoate

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• altitude sickness prevention [Insufficient Evidence]
• anemia [Insufficient Evidence]
• angina [Possibly Effective]
• anthracycline-induced cardiotoxicity [Insufficient Evidence]
• ARDS prevention [Insufficient Evidence]
• asthma [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• beta-thalassemia [Insufficient Evidence]
• breast CA, adjuvant tx [Insufficient Evidence]
• CABG [Insufficient Evidence]
• CHF [Insufficient Evidence]
• CKD [Possibly Ineffective]
• cognitive impairment [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• critical illness (trauma) [Insufficient Evidence]
• cystic fibrosis [Insufficient Evidence]
• dental caries prevention [Insufficient Evidence]
• dental hypersensitivity [Insufficient Evidence]
• diabetes mellitus [Insufficient Evidence]
• diabetic foot ulcers [Insufficient Evidence]
• diabetic neuropathy [Insufficient Evidence]
• erectile dysfxn [Possibly Effective]
• female infertility [Insufficient Evidence]
• head/neck CA [Insufficient Evidence]
• heart failure [Insufficient Evidence]
• heart transplant [Insufficient Evidence]
• HTN [Possibly Effective]
• HTN, pregnancy-induced [Possibly Effective]
• hypercholesterolemia [Possibly Ineffective]
• impaired glucose tolerance [Insufficient Evidence]
• interstitial cystitis [Insufficient Evidence]
• intrauterine growth restriction [Insufficient Evidence]
• male infertility [Insufficient Evidence]
• MELAS syndrome [Insufficient Evidence]
• MI [Possibly Ineffective]
• migraine [Insufficient Evidence]
• muscle wasting, HIV/AIDS-related [Insufficient Evidence]
• muscular dystrophy [Insufficient Evidence]
• necrotizing enterocolitis prevention [Possibly Effective]
• nephrotoxicity, cyclosporine-induced [Insufficient Evidence]
• nitrate tolerance [Insufficient Evidence]
• obesity [Insufficient Evidence]
• oral mucositis [Insufficient Evidence]
• periodontitis [Insufficient Evidence]
• peripheral arterial dz [Possibly Effective]
• physical performance [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• postop infection [Insufficient Evidence]
• postop recovery [Insufficient Evidence]
• pre-eclampsia [Possibly Effective]
• pressure ulcer [Insufficient Evidence]
• preterm labor prevention [Insufficient Evidence]
• PTCA restenosis prevention [Insufficient Evidence]
• radiation dermatitis [Insufficient Evidence]
• renal transplant [Insufficient Evidence]
• respiratory infections [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• sexual dysfxn [Insufficient Evidence]
• sickle cell dz [Insufficient Evidence]
• stress [Insufficient Evidence]
• tuberculosis [Possibly Ineffective]
• valproic acid toxicity [Insufficient Evidence]
• wound healing [Possibly Ineffective]